Celgene sweetened the pot for exec team ahead of Bristol-Myers merger announcement
A beleaguered Celgene $CELG, which was reportedly in merger talks with Bristol-Myers $BMY since September, had hatched a plan to sweeten the pot for its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
